Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
24 participants
INTERVENTIONAL
2023-07-10
2027-10-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cervical Facet Injection of Corticosteroids for the Management of Cervicobrachialgia
NCT07084285
Effectiveness of Cervical Transforaminal Epidural Steroid Injection
NCT04544683
Placebo-controlled Trial of Transdiscal Radiofrequency Annuloplasty
NCT00750191
Duraplasty for Acute Traumatic Spinal Cord Injury
NCT07280351
Clinical Evaluation of Direct Dorsal Column Stimulation
NCT02020460
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
BCPHD-D5W with usual care
Bilateral cervical plexus hydrodissection with D5W (BCPHD-D5W) at 0, 2, 4, and 8 weeks.
All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
BCPHD with D5W
D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
Waiting period with usual care
All helpful treatment methods already underway are continued. Other new treatment methods are discouraged.
Waiting period with usual care
Same as previous group description
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BCPHD with D5W
D5W is injected under the investing fascia of the sternocleidomastoid muscle (SCM) using ultrasound guidance in order to infiltrate the space containing the cervical plexus. This is performed on both sides.
Waiting period with usual care
Same as previous group description
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Reliable transportation
* Comfortable with computers
* Tried 2 or more medications for treatment of PTSD symptoms
* Tried 2 or more non-medication treatments for PTSD symptom
* No known life-threatening illness
* Not taking daily narcotics
* Not having 3or more alcoholic drinks on an average day
* No active suicidal plans
* No major surgery plans
* No major life stress that might interfere with completing study
* Symptoms for more than 1 year
* Not planning to move for next 18 months.
* Living within an hour of Portlland, OR, Madison, WI, or Lexington, KY
* Wiling to provide 2 email and 2 phone contact methods
* Willing to answer questions on multiple occasions over the course of a year.
* Willing to be assigned to 3 months of usual care treatment
* No diagnosis of schizophrenia, Borderline Personality Disorder, or Bipolar Disorder.
* No severe needle phobia
* Chronic pain ≤ 5/10
* PCL-C score ≥ 50
19 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Paul Johnson, D.O.
UNKNOWN
Eric Phillippi, M.D.
UNKNOWN
Ryan Wood, N.D.
UNKNOWN
Danesh Mazloomdoost
UNKNOWN
Dr. Dean Reeves Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Dean Reeves
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kenneth D Reeves, M.D.
Role: PRINCIPAL_INVESTIGATOR
Dr. Dean Reeves Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Danesh Mazloomdoost
Lexington, Kentucky, United States
Paul W. Johnson, D.O., Clinic.
Portland, Oregon, United States
NW Regen
Tigard, Oregon, United States
Eric Phillippi M.D. Clinic
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Rae Olmsted KL, Bartoszek M, Mulvaney S, McLean B, Turabi A, Young R, Kim E, Vandermaas-Peeler R, Morgan JK, Constantinescu O, Kane S, Nguyen C, Hirsch S, Munoz B, Wallace D, Croxford J, Lynch JH, White R, Walters BB. Effect of Stellate Ganglion Block Treatment on Posttraumatic Stress Disorder Symptoms: A Randomized Clinical Trial. JAMA Psychiatry. 2020 Feb 1;77(2):130-138. doi: 10.1001/jamapsychiatry.2019.3474. Erratum In: JAMA Psychiatry. 2020 Feb 1;77(2):218. doi: 10.1001/jamapsychiatry.2019.4511. JAMA Psychiatry. 2020 Sep 1;77(9):982. doi: 10.1001/jamapsychiatry.2020.1829.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DextrosePTSD1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.